Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations
Cancer Treatment Reviews · 2024-06 · 127 · 102751
DOI: 10.1016/j.ctrv.2024.102751 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-06. Verfasst von Layal Rached und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Department of Therapeutic Innovations and Early Trials, 94805 Villejuif, France. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapy associated with Immune Checkpoint Inhibitors is currently the standard of care in several tumor indications. This combination approach improves progression free survival (PFS), overall survival (OS) and complete pathological response (pCR) in several cancer types both in the early and metastatic approaches. However, the distinct spectrum of toxicities between cytotoxic side effects and immune related adverse events (irAEs) with similar clinical presentations and different management strategies remains a challenge in daily practice for healthcare professionals. This review summarizes the most common toxicities reported in the randomized clinical trials that led to the subsequent FDA approval of these combinations, across tumor indications. We cite in particular: non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, squamous cell carcinoma of the head and neck, gastric carcinoma, esophageal carcinoma, cervical carcinoma and biliary tract carcinoma. We found that the combination of chemotherapy and immunotherapy was associated with an increased incidence of all grade adverse events (RR 1.11 [1.09; 1.12]) without an excess in treatment related mortality when compared to chemotherapy alone. We report also an increase in the incidence of serious adverse events (grade ≥ 3) (RR 1.16 [1.10;1.24]); in particular: high grade diarrhea, dyspnea, fatigue, rash and elevated liver enzymes. Together with the collaboration of our institutional network of organ specialists with expertise in irAEs, we propose practical recommendations for physicians to enhance clinical care and management of patients undergoing treatment with combined ICI immunotherapy and chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gustave Roussy, Department of Therapeutic Innovations and Early Trials, 94805 Villejuif, France.
- Gustave Roussy, Interdisciplinary Department for the Organization of Patient Pathways, 94805 Villejuif, France.
- Paris Saclay University and Gustave Roussy, Department of Medical Oncology, 94805 Villejuif, France.
- University Hospital of Bicêtre and Université Paris-Saclay, Department of Gastroenterology, 94270 Le Kremlin Bicêtre, France.
- AP-HP Paul-Brousse Hospital, Hepato-Biliary Center, Inserm Unit 1193, Paris-Saclay University, Hepatinov FHU, Reference Center for Inflammatory Biliary Tract Diseases and Autoimmune Hepatitis, Villejuif, France.
- Paris-Saclay University, Faculty of Medicine, INSERM UMR_S999, 94270 Le Kremlin-Bicêtre, France; Pneumology and Lung Transplant Department, Marie-Lannelongue Hospital, Le Plessis-Robinson, France.
Zitieren
APA
Rached, L., Laparra, A., Sakkal, M., Danlos, F. X., Barlesi, F., Carbonnel, F., De Martin, E., Ducreux, M., Even, C., Le Pavec, J., Michot, J. M., M Ribeiro, J., Scotte, F., Ponce Aix, S., Lambotte, O., Baldini, C., & Champiat, S. (2024). Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations. Cancer Treatment Reviews, 127, 102751. https://doi.org/10.1016/j.ctrv.2024.102751
Vancouver
Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations. Cancer Treatment Reviews. 2024;127:102751. doi:10.1016/j.ctrv.2024.102751
BibTeX
@article{Rached2024,
author = {Rached, Layal and Laparra, Ariane and Sakkal, Madona and Danlos, François-Xavier and Barlesi, Fabrice and Carbonnel, Franck and De Martin, Eleonora and Ducreux, Michel and Even, Caroline and Le Pavec, Jerome and Michot, Jean-Marie and M Ribeiro, Joana and Scotte, Florian and Ponce Aix, Santiago and Lambotte, Olivier and Baldini, Capucine and Champiat, Stéphane},
title = {Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {127},
pages = {102751},
doi = {10.1016/j.ctrv.2024.102751}
}
EUVIMED